Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Infectious Disease Reports
Published in: Current Infectious Disease Reports 4/2015

01-04-2015 | Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

The Challenges and Promise of HIV-Infected Donors for Solid Organ Transplantation

Authors: Aaron Richterman, Emily Blumberg

Published in: Current Infectious Disease Reports | Issue 4/2015

Login to get access

Abstract

Solid organ transplantation is now the standard of care for many HIV-infected patients with end-stage kidney or liver disease. There is an overall organ shortage that affects all transplant candidates, including those with HIV. The use of HIV-infected donors could help alleviate this shortage. The precedent for this approach was set in South Africa, where promising short-term outcomes have been reported in a limited number of HIV-infected recipients of kidney transplants from HIV-infected donors. As a consequence, the HIV Organ Policy Equity (HOPE) Act was passed in the United States, legalizing research into HIV-infected organ donation. In this review, we discuss some of the key issues related to HIV-infected organ donation, including the need for transplant in HIV-infected populations, characterization of the potential donor pool in the USA, criteria for donor selection, concerns specific to the HIV-infected donor, the ethics of HIV-infected organ donation, and the next steps toward making HIV-infected donation a reality in the USA.
Literature
1.
Smith C, Ryom L, Weber R, Morlat P, Pradier C, Reiss P, et al. Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration. Lancet. 2014;384(9939):241–8.CrossRefPubMed
2.
Weber R, Ruppik M, Rickenbach M, Spoerri A, Furrer H, Battegay M, et al. Decreasing mortality and changing patterns of causes of death in the Swiss HIV Cohort Study. HIV Med. 2013;14(4):195–207.CrossRefPubMed
3.
Spital A. Should all human immunodeficiency virus-infected patients with end-stage renal disease be excluded from transplantation? The views of U.S. transplant centers. Transplantation. 1998;65:1187–91.CrossRefPubMed
4.
Harbell J, Terrault N, Stock P. Solid organ transplants in HIV-infected patients. Curr HIV AIDS Rep. 2013;10(3):217–25.CrossRef
5.
Roland M, Barin B, Carison L, Frassetto L, Terrault N, Hirose R, et al. HIV-infected liver and kidney transplant recipients: 1- and 3-year outcomes. Am J Transplant. 2008;8(2):355–65.CrossRefPubMed
6.
Harbell J, Fung J, Nissen N, Olthoff K, Florman S, Hanto D, et al. Surgical complications in 275 HIV-infected liver and/or kidney transplantation recipients. Surgery. 2012;152(3):376–81.CrossRefPubMedCentralPubMed
7.
Stock P, Barin B, Murphy B, Hanto D, Diego J, Light J, et al. Outcomes of kidney transplantation in HIV-infected recipients. N Engl J Med. 2010;363(21):2004–14. Prospective, multicenter, non-randomized trial of kidney transplant in 150 HIV-infected patients in the USA followed for a median of 1.7 years. Patient survival was similar to HIV-uninfected recipients older than 65 years old. Rejection rates were two to three times higher compared to HIV-uninfected patients, but this did not have an impact on overall short-term graft survival.CrossRefPubMedCentralPubMed
8.
Touzot M, Pillebout E, Matignon M, Tricot L, Viard J, Rondeau E, et al. Renal transplantation in HIV-infected patients: the Paris experience. Am J Transplant. 2010;10(10):2263–9.CrossRefPubMed
9.
Pelletier S, Norman S, Christensen L, Stock P, Port F, Merion R. Review of transplantation in HIV patients during the HAART era. Clin Transpl. 2004; p. 63–82.
10.
Roth D, Gaynor J, Reddy K, Cianci G, Sageshima J, Kupin W, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol. 2011;22(6):1152–60.CrossRefPubMedCentralPubMed
11.
Kumar M, Sierka D, Damask A, Fyfe B, McAlack R, Heifets M, et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int. 2005;67(4):1622–9.CrossRefPubMed
12.
Ragni M, Belle S, Im K, Neff G, Roland M, Stock P, et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J Infect Dis. 2003;188(10):1412–20.CrossRefPubMed
13.
Cooper C, Kanters S, Klein M, Chaudhury P, Marotta P, Wong P, et al. Liver transplant outcomes in HIV-infected patients: a systematic review and meta-analysis with synthetic cohort. AIDS. 2011;25(6):777–86. Systematic meta-analysis evaluating liver transplant in patients co-infected with HIV and viral hepatitis. Outcomes were similar to HIV-uninfected recipients in Europe and slightly worse than those in the USA. HIV/HBV co-infection was associated with optimal survival.CrossRefPubMed
14.
Coffin C, Stock P, Dove L, Berg C, Nissen N, Curry M, et al. Virologic and clinical outcomes of hepatitis B virus infection in HIV-HBV coinfected transplant recipients. Am J Transplant. 2010;10(5):1268–75.CrossRefPubMedCentralPubMed
15.
16.
17.
18.
Sawinski D, Wyatt C, Casagrande L, Myoung P, Bijan I, Akalin E, et al. Factors associated with failure to list HIV-positive kidney transplant candidates. Am J Transplant. 2009;9(6):1467–71.CrossRefPubMedCentralPubMed
19.
Wyatt C, Maliambro K, Klotman P. Recent progress in HIV-associated nephropathy. Annu Rev Med. 2012;63:147–59.CrossRefPubMed
20.
Rasch M, Helleberg M, Feldt-Rasmussen B, Kronborg G, Larsen C, Pedersen C, et al. Increased risk of dialysis and end-stage renal disease among HIV patients in Denmark compared with the background population. Nephrol Dial Transplant. 2014;29(6):1232–8.CrossRefPubMed
21.
Ragni M, Eghtesad B, Schlesinger K, Dvorchik I, Fung J. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl. 2005;11(11):1425–30.CrossRefPubMed
22.
Trullas J, Cofan F, Barril G, Martinez-Castelao A, Jofre R, Rivera M, et al. Outcome and prognostic factors in HIV-1-infected patients on dialysis in the cART era: a GESIDA/SEN cohort study. J Acquir Immune Defic Syndr. 2011;57(4):276–83.CrossRefPubMed
23.
Reardon S. Hopeful act: a rebel transplants organs from HIV-positive donors. Nat Med. 2014;20(10):1086–88.CrossRefPubMed
24.
Muller E, Kahn D, Mendelson M. Renal transplantation between HIV-positive donors and recipients. N Engl J Med. 2010;362(24):2336–7. Initial report of 4 HIV-infected recipients of kidneys from HIV-infected donors. The donors were antiretroviral-naïve but had no history of opportunistic infection and normal renal biopsies without proteinuria. The recipients were given standard immunosuppressive treatment post-transplant and at 12 months had good renal function and no significant acute rejection.CrossRefPubMed
25.
Muller E, Barday Z, Mendelson M, Kahn D. Renal transplantation between HIV-positive donors and recipients justified. S Afr Med J. 2012;102(6):497–8.PubMed
26.
Muller E. Kidney transplantation in HIV positive patients from HIV positive donors: 3–5 year results of prospective non-randomized study. Oral presentation at: World Transplant Congress. 2014; San Francisco, California.
27.
Frassetto L, Browne M, Cheng A, Wolfe A, Roland M, Stock P, et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am J Transplant. 2007;7(12):2816–20.CrossRefPubMed
28.
Odim J. The HOPE Act: criteria for transplanting kidneys or livers from HIV+ donors into HIV+ recipients. Oral presentation at: 54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). 2014; Washington, DC.
29.
Gardner E, McLees M, Steiner J, Del Rio C, Burman W. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52(6):793–800.CrossRefPubMedCentralPubMed
30.
Bradley H, Hall H, Wolitski R, Van Handel M, Stone A, LaFlam M, et al. Vital signs: HIV diagnosis, care, and treatment among persons living with HIV—United States, 2011. MMWR Morb Mortal Wkly Rep. 2014 Nov 25; 63(Early Release): p. 1–6.
31.
Staples Jr C, Rimland D, Dudas D. Hepatitis C in the HIV (human immunodeficiency virus) Atlanta V.A. (Veterans Affairs Medical Center) Cohort Study (HAVACS): the effect of coinfection on survival. Clin Infect Dis. 1999;29(1):150.CrossRefPubMed
32.
33.
Terrault N, Roland M, Schiano T, Dove L, Wong M, Poordad F, et al. Outcomes of liver transplantation in HCV-HIV coinfected recipients. Liver Transplant. 2012;18(6):716–26. Prospective, multicenter cohort study of 89 HIV/HCV co-infected liver transplant recipients in the USA compared with 235 HCV-monoinfected liver recipients and all liver transplant recipients over the age of 65 in the USA. Both graft and patient survival were lower for HIV/HCV co-infected recipients compared to HCV-monoinfected recipients, and rates of acute rejection were higher. Use of an HCV-infected donors was an independent predictor of graft loss in HIV/HCV co-infected recipients.CrossRef
34.
Miro J, Montejo M, Castells L, Rafecas A, Moreno S, Aguero F, et al. Outcome of HCV/HIV-coinfected liver transplant recipients: a prospective and multicenter cohort study. Am J Transplant. 2012;12(7):1866–76. Prospective, multicenter cohort study of 84 HIV/HCV co-infected liver transplant recipients in Spain compared with 252 HCV-monoinfected patients matched by calendar year, age, gender, HBV co-infection, and history of hepatocellular carcinoma. Five-year survival was lower among HIV/HCV co-infected recipients than in HCV-monoinfected recipients.CrossRefPubMed
35.
Xia Y, Friedmann P, Yaffe H, Phair J, Gupta A, Kayler L. Effect of HCV, HIV and coinfection in kidney transplant recipients: mate kidney analysis. Am J Transplant. 2014;14(9):2037–47.CrossRefPubMed
36.
Campos-Verela I, Peters M, Terrault N. Advances in therapy for HIV-HCV coinfected patients in the liver transplant setting. Clin Infect Dis. 2014 Sep 16; Epub ahead of print.
37.
Campos-Varela I, Straley S, Agudelo E, Carlson L, Terrault N. Sofosbuvir, simeprevir plus ribavirin for treatment of HCV recurrence in HIV-HCV coinfected liver transplant recipients. Liver Transpl. 2014 Oct 20; Epub ahead of print.
38.
Kwo P, Mantry P, Coakley E, Te H, Vargas H, Brown R, et al. An interferon-free antiviral regimen for HCV after liver transplantation. N Engl J Med. 2014 Nov 11; Epub ahead of print.
39.
Chang M, Olsen S, Pichardo E, Stiles J, Rosenthal-Cogan L, Brubaker W, et al. Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: a 12-year experience. Transplantation. 2013;95(7):960–5.CrossRefPubMed
40.
Veroux M, Corona D, Ekser B, Giaquinta A, Tallarita T, De Martino C, et al. Kidney transplantation from hepatitis B virus core antibody-positive donors: prophylaxis with hepatitis B immunoglobulin. Transplant Proc. 2011;43(4):967–70.CrossRefPubMed
41.
Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients (SRTR). OPTN/SRTR 2012 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration; 2014.
42.
43.
Boyarsky B, Hall E, Singer A, Montgomery R, Gebo K, Segev D. Estimating the potential pool of HIV-infected deceased organ donors in the United States. Am J Transplant. 2011;11:1209–17. Analysis of HIV-infected patient deaths captured by two databases that results in estimation of over 500 potential HIV-infected deceased donors dying in the USA each year.CrossRefPubMedCentralPubMed
44.
Richterman A, Lee D, Reese P, Sawinski D, Abt P, Thomasson A, et al. Suitability of HIV infected patients for deceased organ donation [abstract H-1199a]. In Final Program of 54th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2014; Washington, DC. p. 410–411.
45.
Canaud G, Dejucq-Rainsford N, Avettand-Fenoel V, Viard J, Anglicheau D, Bienaime F, et al. The kidney as a reservoir for HIV-1 after renal transplantation. J Am Soc Nephrol. 2014;25(2):407–19.CrossRefPubMedCentralPubMed
46.
Loutfy M, Wu W, Letchumanan M, Bondy L, Antoniou T, Margolese S, et al. Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PLoS ONE. 2013;8(2):e55747.CrossRefPubMedCentralPubMed
47.
Stock P, Barin B, Hatano H, Rogers R, Roland M, Lee T, et al. Reduction of HIV persistence following transplantation in HIV-infected kidney transplant recipients. Am J Transplant. 2014;14(5):1136–41.CrossRefPubMed
48.
Gilliam B, Heredia A, Devico A, Le N, Bamba D, Bryant J, et al. Rapamycin reduces CCR5 mRNA levels in macaques: potential applications in HIV-1 prevention and treatment. AIDS. 2007;21(15):2108–10.CrossRefPubMed
49.
Heredia A, Latinovic O, Gallo R, Mlikyan G, Reitz M, Le N, et al. Reduction of CCR5 with low-dose rapamycin enhances the antiviral activity of vicriviroc against both sensitive and drug-resistant HIV-1. Proc Natl Acad Sci U S A. 2008;105(51):20476–81.CrossRefPubMedCentralPubMed
50.
Haïm-Boukobza S, Balabanian K, Teicher E, Bourgeade M, Perlemuter G, Roque-Afonso A, et al. Blockade of CCR5 to protect the liver graft in HIV/HCV co-infected patients. J Hepatol. 2013;59(3):613–5.CrossRefPubMed
51.
Stock P, Roland M. Evolving clinical strategies for transplantation in the HIV-positive recipient. Transplantation. 2007;84(5):563–71.CrossRefPubMed
52.
53.
Mgbako O, Glazier A, Blumberg E, Reese P. Allowing HIV-positive organ donations: ethical, legal and operational considerations. Am J Transplant. 2013;13:1636–42. Discussion of the ethical considerations justifying the legalization of HIV-infected organ donation in the USA, and some of the key operational issues that will need to be considered to make HIV-infected organ donation a reality in the USA.CrossRefPubMed
54.
Wispelwey B, Zivotofsky A, Jotkowitz A. The transplantation of solid organs from HIV-positive donors to HIV-negative recipients: ethical implications. J Med Ethics. 2014 Jun 4; Epub ahead of print.
55.
Kern R, Seethamraju H, Blanc P, Sinha N, Loebe M, Golden J, et al. The feasibility of lung transplantation in HIV-seropositive patients. Ann Am Thorac Soc. 2014;11(6):882–9.CrossRefPubMed
56.
Bertani A, Grossi P, Vitulo P, D′Ancona G, Arcadipane A, Nanni Costa A, et al. Successful lung transplantation in an HIV- and HBV-positive patient with cystic fibrosis. Am J Transplant. 2009;9(9):2190–6.CrossRefPubMed
57.
Uriel N, Jorde U, Cotarlan V, Colombo P, Farr M, Restaino S, et al. Heart transplantation in human immunodeficiency virus–positive patients. J Heart Lung Transplant. 2009;28(7):667–9.CrossRefPubMed
58.
Uriel N, Nahumi N, Colombo P, Yuzefpolskaya M, Restaino S, Han J, et al. Advanced heart failure in patients infected with human immunodeficiency virus: is there equal access to care? J Heart Lung Transplant. 2014;33(9):924–30.CrossRefPubMed
Metadata
Title
The Challenges and Promise of HIV-Infected Donors for Solid Organ Transplantation
Authors
Aaron Richterman
Emily Blumberg
Publication date
01-04-2015
Publisher
Springer US
Published in
Current Infectious Disease Reports / Issue 4/2015
Print ISSN: 1523-3847
Electronic ISSN: 1534-3146
DOI
https://doi.org/10.1007/s11908-015-0471-z

Other articles of this Issue 4/2015

Current Infectious Disease Reports 4/2015 Go to the issue

Central Nervous System Infections (J Lyons, Section Editor)

Imaging in Neurologic Infections II: Fungal and Viral Diseases

Healthcare Associated Infections (G Bearman, Section Editor)

Hand Hygiene Compliance Monitoring: the State of the Art

HIV/AIDS (R MacArthur, Section Editor)

What We Know and What We Do Not Know About Factors Associated with and Interventions to Promote Antiretroviral Adherence

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Transplant Tourism: Understanding the Risks

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Value of Solid Organ Transplant-Trained Pharmacists in Transplant Infectious Diseases

Transplant and Oncology (M Ison and N Theodoropoulos, Section Editors)

Live Virus Vaccines in Transplantation: Friend or Foe?
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits